A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

Clinical trial NCT05456867 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05456867
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

NSCLC, Non-small-cell Lung Carcinoma

Start date: 2022-05-31
Primary completion: 2026-11-30
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.